Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
This double-blind, controlled trial (n=90) aims to investigate the effect of a single high dose of psilocybin therapy (30mg) versus a very low dose (1mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid Use Disorder (OUD).
Details
Randomized, double-blind, parallel-group trial comparing a single 30 mg oral psilocybin session to a 1 mg very low-dose session administered after outpatient buprenorphine induction in adults with OUD (n=90).
Participants receive 2–4 preparatory sessions, an open-label buprenorphine maintenance phase, and follow-up visits at 1, 2, 3, 4, 6 and 8 weeks post-dosing to assess opioid abstinence, treatment retention, quality of life, craving, tobacco use, and safety.